Predictive Immune Biomarkers for COVID-19 Pathogenesis (COVIDBioToul)
COVID-19
About this trial
This is an interventional basic science trial for COVID-19 focused on measuring SARS-CoV-2, COVID-19, predictive medicine, pathophysiology, immune responses
Eligibility Criteria
Inclusion Criteria:
For COVID-19 hospitalized patients
- Polymerase chain reaction (PCR) proven SARS-CoV-2 infection
- Participation to Toulouse clinical cohort
- Having signed consent for inclusion in the Toulouse biobanks
For COVID-19 healthcare workers attending dedicated clinics
- PCR proven SARS-CoV-2 infection
- Having signed consent for inclusion in the Toulouse biobanks
Exclusion Criteria:
- Pregnancy or breastfeeding
- Participation in another interventional clinical study involving exploratory treatment or blood sampling.
Sites / Locations
- Purpan University Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
hospitalized patients
healthcare workers
very well-defined population of COVID-19 patients with the following outcomes: Patients with severe disease requiring on admission ICU management for ARDS, Non-severe hospitalized patients with secondary clinical worsening requiring ICU management, Non-severe hospitalized patients without clinical worsening requiring ICU management.
mildly symptomatic patients among healthcare workers attending outpatient dedicated clinics will be recruited